Top Page
dorsaVi Limited
(Sydney:DVL)
dorsaVi Limited (DVL) vs. iShares MSCI Australia ETF (EWA)
dorsaVi Limited Business Overview & Revenue Model
dorsaVi Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.13M | 1.13M | 1.30M | 1.75M | 2.35M | 1.87M |
| Gross Profit | 971.82K | 971.82K | 1.18M | -798.43K | -1.45M | -1.74M |
| EBITDA | -1.82M | -1.82M | -1.60M | -1.88M | -1.53M | -2.29M |
| Net Income | -1.52M | -1.52M | -1.25M | -1.82M | -1.54M | -2.41M |
Balance Sheet | ||||||
| Total Assets | 3.97M | 3.97M | 2.18M | 2.69M | 3.36M | 5.42M |
| Cash, Cash Equivalents and Short-Term Investments | 2.29M | 2.29M | 478.10K | 878.72K | 449.70K | 2.80M |
| Total Debt | 156.89K | 156.89K | 190.17K | 321.85K | 1.18M | 1.18M |
| Total Liabilities | 1.14M | 1.14M | 1.16M | 1.01M | 2.13M | 2.95M |
| Stockholders Equity | 2.84M | 2.84M | 1.02M | 1.68M | 1.22M | 2.48M |
Cash Flow | ||||||
| Free Cash Flow | -956.83K | -956.83K | -622.08K | -1.02M | -2.25M | -2.36M |
| Operating Cash Flow | -956.83K | -956.83K | -600.90K | -967.41K | -2.15M | -2.27M |
| Investing Cash Flow | -304.00K | -304.00K | -21.18K | -51.65K | -100.34K | -85.41K |
| Financing Cash Flow | 3.08M | 3.08M | 227.06K | 1.45M | -92.25K | 3.47M |
dorsaVi Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
43 Neutral | AU$59.65M | -26.50 | -78.66% | ― | -13.40% | 4.76% | |
39 Underperform | AU$13.17M | ― | ― | ― | -51.64% | -21.74% | |
39 Underperform | AU$4.36M | -1.19 | ― | ― | -4.86% | 64.36% | |
38 Underperform | AU$8.47M | -0.63 | -135.89% | ― | -21.60% | -657.00% | |
37 Underperform | AU$5.15M | -0.76 | -283.40% | ― | -74.76% | 42.11% |
dorsaVi Limited Corporate Events
dorsaVi Limited has appointed Mathew Regan as the new Group Chief Executive Officer, effective November 1, 2025. Regan, with a strong background in digital health, AI, and advanced manufacturing, is expected to lead the company through a pivotal phase of growth. His previous success at Artrya Limited in reshaping AI-driven platforms and securing FDA clearances positions him well to drive dorsaVi’s global expansion and commercialization of next-generation technologies. The company is focusing on leveraging its RRAM-enabled sensor capabilities across multiple industries, with initiatives like the Reflex platform and the launch of Artemis Labs to accelerate development in robotics and human-machine interfaces.
dorsaVi Limited has initiated a process to engage with semiconductor development partners to explore scaling down its oxide-based Resistive Random-Access Memory (RRAM) technology to the 22 nm process node. This move aims to enhance the technology’s density, speed, and power efficiency, crucial for next-generation edge and wearable computing systems. The 22 nm node is recognized for its manufacturability and performance, providing a solid foundation for dorsaVi’s adaptive RRAM arrays in applications such as biosensing and robotics, where low latency and independence from cloud computing are essential. The company plans to establish a joint evaluation plan with selected partners to guide future developments and potential foundry engagement, marking a significant step in advancing their sensor and robotics products into more intelligent systems.
dorsaVi Limited has made significant strides in its RRAM sensor technology, initiating comprehensive testing in Singapore for biomedical applications such as electromyography and electrocardiography. The company has also signed a five-year sales agreement with a major U.S. physical therapy franchise, indicating strong market expansion potential. Additionally, dorsaVi’s ViMove+ product is showing promising growth in the U.S. market, with acquisition trends significantly higher than historical rates. The company’s financial position has strengthened with a cash balance increase, supported by a successful $5.0 million placement to accelerate RRAM and robotics technology development.
dorsaVi Limited has announced a proposed issue of 2,342,009 ordinary fully paid securities, with an expected issue date of December 3, 2025. This move aims to strengthen the company’s financial position and potentially enhance its market presence, offering significant implications for its stakeholders and industry positioning.
dorsaVi Limited has announced a proposed issue of 24 million performance rights, with the issue date set for December 3, 2025. This move is part of a placement or other type of issue, indicating a strategic effort to potentially raise capital or incentivize stakeholders, which could impact the company’s operations and market positioning within the health technology sector.
dorsaVi Limited has announced its 2025 Annual General Meeting scheduled for November 26, 2025, in Melbourne. Shareholders are encouraged to vote by proxy due to potential changes in meeting conditions, and the company emphasizes digital access to meeting documents to streamline communication and ensure shareholder engagement.
dorsaVi Limited has announced its upcoming Annual General Meeting scheduled for November 26, 2025, in Melbourne. Key agenda items include the adoption of the Remuneration Report, the election of Mr. Leigh Travers as a Director, and the approval of issuing Performance Rights to Mr. Mathew Regan. These resolutions, if passed, could influence the company’s governance structure and executive compensation, potentially impacting its strategic direction and stakeholder relations.
dorsaVi Limited has announced the cessation of 1,412,303 securities due to the expiry of options or other convertible securities without exercise or conversion as of October 7, 2025. This announcement reflects a change in the company’s issued capital and may impact its financial structure and investor relations.
dorsaVi Limited has announced its 2025 Annual General Meeting, scheduled for November 26, 2025, with nominations for director positions closing on October 15, 2025. This meeting is a significant event for the company, providing an opportunity for stakeholders to engage with the company’s leadership and discuss strategic directions. The announcement underscores dorsaVi’s commitment to transparency and governance, potentially impacting its market positioning and stakeholder relations.
dorsaVi Limited has reported significant growth in the US Physical Therapy market with its ViMove+ product, achieving a 15-fold increase in monthly acquisition trends. The company’s strategic expansion, including successful face-to-face training sessions in Arizona, has resulted in a 90% conversion rate, indicating strong demand and validating their rollout strategy. This growth is supported by the adoption of their products by US surgeons and the development of a hardware roadmap incorporating advanced technology, positioning dorsaVi for continued success in a lucrative and expanding market.
dorsaVi Limited has announced a significant technical breakthrough with its RRAM Reflex Platform, which has demonstrated superior efficiency and speed compared to state-of-the-art digital edge AI systems. The platform achieves sub-microsecond reflex latency and nanojoule-level energy use, positioning it as a transformative technology for next-generation robotics and biomedical systems, with implications for improved stability and efficiency in real-world applications.
dorsaVi Limited has updated its corporate governance statement for the financial year ending June 30, 2025, in compliance with ASX Listing Rules. The statement, approved by the board, outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations. By providing a detailed account of its governance practices, dorsaVi aims to ensure transparency and accountability to its stakeholders, reinforcing its commitment to high standards of corporate governance.
DorsaVi Limited has released its annual report for the year ending June 30, 2025. The report highlights the company’s continued commitment to leveraging its wearable sensor technology to enhance clinical and workplace safety outcomes. Listed on the Australian Securities Exchange, DorsaVi’s strategic focus remains on expanding its market presence and improving operational efficiencies, which could have positive implications for stakeholders and strengthen its position within the health technology industry.
dorsaVi Limited has announced that Starfish Technology Fund II Nominees B Pty Ltd, HV Lodge LLC, and Mantra Secondary Opportunities II SCA-SIF have ceased to be substantial holders in the company as of August 28, 2025. This change is attributed to the dilution of shares due to issuances, affecting over 48 million fully paid ordinary shares, which may impact the company’s shareholder structure and influence in the market.
Starfish Technology Fund II Nominees A Pty Ltd and Perpetual Trustee Company Limited have ceased to be substantial holders in dorsaVi Limited as of August 28, 2025. This change is primarily due to the dilution of shares resulting from new share issuances, affecting a total of 48,763,230 fully paid ordinary shares. This development may impact dorsaVi’s shareholder structure, potentially influencing its market strategy and stakeholder relationships.
dorsaVi Limited has announced a significant technical milestone with the successful engineering validation of its RRAM-powered Reflex Platform. This platform is capable of executing neural reflex decisions in less than 0.8 microseconds with ultra-efficient energy consumption, marking a critical advancement in robotics and biomedical applications. The validation confirms that the memory element is no longer a bottleneck, shifting focus to peripheral components, and positions dorsaVi as a potential leader in the industry.
dorsaVi has announced a five-year sales agreement with Select Medical, a leading US-based network of outpatient physical therapy centers, to offer its FDA-approved products across over 1,900 locations. This partnership follows an 18-month development pilot that ensured the technology met therapists’ needs, focusing on rehabilitation and return-to-play assessments for injured athletes. The agreement marks a significant opportunity for dorsaVi to enhance its presence in the US market, potentially impacting patient assessment and rehabilitation practices.
dorsaVi Limited has announced a proposed issue of 2,000,000 unlisted performance rights, with the issue date set for November 4, 2025. This move is part of a placement or other type of issue, which may impact the company’s market positioning and stakeholder interests by potentially enhancing its financial flexibility and growth opportunities.
dorsaVi Limited has appointed Ed Doller, a veteran in the semiconductor industry, as a Strategic Adviser to guide the company through its transition into advanced technologies such as RRAM-enabled systems and edge AI. This strategic move is part of dorsaVi’s broader plan to expand its technological capabilities and market reach, with a focus on real-time biomedical sensing and autonomous motion platforms, potentially positioning the company as a leader in ultra-low power edge AI applications.
dorsaVi Limited has announced the issuance of 24,750,000 fully paid ordinary shares, as confirmed in their Section 708A Cleansing Notice under the Corporations Act 2001. This move reflects the company’s compliance with regulatory requirements and may impact its financial operations and stakeholder interests by potentially increasing capital for further development and expansion in its target markets.
DorsaVi Limited has announced the quotation of 24,750,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code DVL. This move follows a previously announced transaction and marks a significant step in the company’s market activities, potentially impacting its operations and positioning within the industry.
dorsaVi Limited has issued over 101 million fully paid ordinary shares without investor disclosure under the Corporations Act, complying with relevant legal provisions. This strategic move is expected to enhance the company’s operational capabilities and strengthen its market position in the motion analysis technology industry, potentially impacting stakeholders positively by expanding its financial base.
dorsaVi Limited announced the issuance of 1,092,812 fully paid ordinary shares to be quoted on the ASX, aimed at settling existing liabilities. This move is expected to strengthen the company’s financial position, potentially enhancing its market presence and operational capabilities, which could have positive implications for stakeholders and investors.
dorsaVi Limited has announced a new application for the quotation of 100,250,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DVL, effective August 29, 2025. This move is part of previously announced transactions and reflects the company’s ongoing efforts to enhance its market presence and liquidity, potentially impacting its operational capabilities and investor relations positively.
DorsaVi Limited reported a 13.9% decrease in revenues from ordinary activities, totaling $1,148,959 for the year ending June 30, 2025. The company experienced a 21.7% increase in losses, amounting to $1,517,753, attributed to consistent costs compared to the previous year. Despite the financial losses, DorsaVi improved its net assets by $1,812,306, reaching $2,835,656, primarily due to capital raisings. This financial performance highlights challenges in revenue generation but shows strengthened financial positioning through asset growth.
dorsaVi Limited has appointed Mathew Regan as Group Chief Executive Officer, effective November 1, 2025, to lead the company’s next phase of growth. Regan, with a strong background in digital health and AI, is expected to drive the commercialization of dorsaVi’s next-generation RRAM-enabled sensor technologies and expand its applications across various industries. This strategic leadership change aims to enhance dorsaVi’s global expansion and strengthen its position in high-growth markets, leveraging recent innovations and the launch of Artemis Labs to accelerate development and secure new commercial opportunities.
dorsaVi Limited has announced a change in the director’s interest, specifically regarding Andrew James Ronchi. The change involves the acquisition of 2,707,286 quoted shares at a value of $0.028 per share, issued in lieu of accrued annual leave amounts following shareholder approval at the company’s Extraordinary General Meeting on August 15, 2025. This adjustment in shareholding reflects a strategic move by the company to manage executive compensation and align director interests with shareholder value.
DorsaVi Limited announced the issuance of 20 million unlisted options, exercisable at $0.02, set to expire on August 20, 2028. This issuance is part of previously announced transactions and is not intended to be quoted on the ASX. The move could potentially enhance the company’s financial flexibility and support its strategic initiatives.
dorsaVi Limited has issued 88,123,953 fully paid ordinary shares, as announced in a Section 708A Cleansing Notice under the Corporations Act 2001. This strategic move signifies the company’s compliance with regulatory requirements and may enhance its operational capabilities and market presence, potentially impacting stakeholders positively.
DorsaVi Limited has announced the issuance of 20 million performance rights, which are unquoted securities, as part of a transaction previously announced to the market. This move signifies a strategic step by DorsaVi to enhance its financial operations, potentially impacting its market positioning and offering implications for its stakeholders.
dorsaVi Limited has announced the issuance of 40 million unquoted performance rights, as part of a transaction previously disclosed to the market. This move is likely to impact the company’s operations by potentially enhancing its financial flexibility and aligning stakeholder interests, though the securities will not be quoted on the ASX.
DorsaVi Limited has announced the issuance of 1,500,000 unquoted performance rights as of August 20, 2025. This move is part of the company’s strategic financial operations, potentially impacting its equity structure and signaling a focus on incentivizing performance, which may affect stakeholders’ interests.
dorsaVi Limited has announced the application for quotation of 12,500,000 ordinary fully paid securities on the Australian Securities Exchange (ASX), with an issue date of August 20, 2025. This move is part of previously announced transactions and represents a strategic effort to enhance the company’s capital structure, potentially impacting its market position and providing new opportunities for stakeholders.
dorsaVi Limited has announced the issuance of 6,666,667 ordinary fully paid shares to settle outstanding consulting fees. This move aims to streamline financial obligations and potentially improve liquidity, reflecting the company’s strategic efforts to maintain operational stability and investor confidence.
DorsaVi Limited has announced the issuance of new shares to settle outstanding liabilities. A total of 2,707,286 ordinary fully paid securities will be quoted on the ASX, with the issue date set for August 20, 2025. This move is part of the company’s strategy to manage its financial obligations and could impact its market positioning by potentially improving its balance sheet and investor confidence.
dorsaVi Limited has announced the issuance of 6,250,000 ordinary fully paid shares to satisfy consulting services provided to the company. This move is part of their strategic efforts to enhance operational capabilities and potentially strengthen their market position, reflecting a commitment to leveraging expert consultancy for growth and development.
dorsaVi Limited has announced the application for the quotation of 60 million fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility and market presence, potentially impacting its operational capabilities and stakeholder interests positively.
dorsaVi Limited has launched Artemis Labs, a new subsidiary aimed at advancing human movement into digital and robotic systems. This initiative will leverage dorsaVi’s existing sensor technology and newly licensed RRAM IP to create a centralized movement intelligence repository. The subsidiary will focus on developing AI models for real-time applications in robotics, healthcare, and digital systems, potentially transforming how human motion is integrated into machine operations.
dorsaVi Limited has announced a proposed issue of securities, including 62.5 million unlisted options and 125 million fully paid ordinary shares, with the issue date set for August 29, 2025. This strategic move aims to strengthen the company’s financial position and support its growth initiatives, potentially enhancing its market presence and offering new opportunities for stakeholders.
dorsaVi Limited has successfully raised A$5 million through a strategic placement to accelerate the development of its next-generation RRAM sensor systems and expand into edge AI and robotics applications. This funding will enable the company to integrate RRAM-enabled architecture across its FDA-cleared sensors and video-based AI platforms, strengthening its global growth in high-growth technology verticals. The capital infusion is expected to fast-track dorsaVi’s commercialisation roadmap, allowing the company to capitalize on significant growth opportunities in edge computing, artificial intelligence, and robotics innovations.
dorsaVi Limited announced the successful passage of all resolutions at its extraordinary general meeting, as per the Corporations Act and ASX regulations. This outcome supports the company’s strategic initiatives, including share placements and capital issuances, which are expected to enhance its operational capabilities and market position.